Nav: Home

A patent study on the great new hope emerging from marine derived anticancer drugs

June 21, 2017

Anticancer agents targeting microtubule from marine sources hold great potential in the field of cancer therapeutics and are gradually advancing in the clinical setup.

Microtubule dynamics govern crucial cellular functions and this is why microtubules are one of the most attractive anticancer drug targets. Microtubule targeting agents (MTAs) have the ability to treat a wide range of cancers. However, drug induced cytotoxicity and adverse side effects have hindered their development. Another major setback is multiple drug resistance in tumor cells. These limitations have prompted the need to develop novel MTAs from alternative sources, with better therapeutic efficacies. Recently, MTAs from marine sources have grabbed much attention due to their unique tubulin binding features and remarkable ability to reduce tumor progression.

The authors have summarized some of the most promising marine derived MTAs by systematically searching patent databases such as USPTO, Espacenet and WIPO for recent patents published from 2006 up to 2016. After a critical data analysis, only those patents focusing on the chemical synthesis and/or modifications of marine derived MTAs along with a significant demonstration of their in vitro and/or in vivo activity have been reviewed.

The survey of recent patents revealed that chemically modified versions of marine derived MTAs, overcoming drug resistance and their novel combination therapies increasing the overall efficacy, have positioned them as future anticancer blockbusters. Of particular interest are dolastatin, laulimalide, peloruside, hemiasterlin, halichondrin, eribulin mesylate, discodermolide, dictyostatin, cryptophycin and their analogs which have significant antiproliferative potency against a wide array of cancers and are also able to overcome multidrug resistance. A deeper understanding of the molecular mechanisms behind the specific drug interactions and of microtubule molecular biology in general, combined with innovative therapeutic regimen would lead to major advances in the field of cancer therapy.
-end-
For more information about the article, please visit http://www.eurekaselect.com/149076

Reference: De O. (2017). A patent study on the great new hope emerging from marine derived anticancer drugs targeting microtubules, Recent Patents on Anti-Cancer Drug Discovery, DOI: 10.2174/1574892812666170109141003

Bentham Science Publishers

Related Cancer Therapeutics Articles:

Elicio Therapeutics' Darrell Irvine co-authors research published in Science
Elicio Therapeutics, a next generation immuno-oncology company, today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response.
'Green Revolution' in RNAi tools and therapeutics
A team from Nanjing University in China reported that the small silencing RNA sequences against HBsAg generated in edible lettuce (Lactuca sativa L.) can specifically bind and inhibit gene expression in p21-HBsAg knock-in transgenic mice and improve liver injury at a relatively low level when compared to synthetic siRNAs.
Texas A&M research team develops bioinks to print therapeutics in 3D
A team of researchers at Texas A&M University has developed an innovative way to print therapeutics in 3D for regenerative medicine.
Newly identified drug targets could open door for esophageal cancer therapeutics
Blocking two molecular pathways that send signals inside cancer cells could stave off esophageal adenocarcinoma (EAC), the most common esophageal malignancy in the United States, according to new research out of Case Western Reserve University School of Medicine.
Yumanity Therapeutics announces publication of paper in Cell Reports
Yumanity Therapeutics, a company focused on discovering transformative therapies to treat neurodegenerative diseases, today announced the publication of study results describing a potential new target for therapeutic intervention in Parkinson's disease and other related disorders.
More Cancer Therapeutics News and Cancer Therapeutics Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...